| Business Summary | | Ligand
Pharmaceuticals
Incorporated
discovers,
develops
and
markets
new
drugs
that
address
critical
unmet
medical
needs
of
patients
in
the
areas
of
cancer,
men's
and
women's
health
and
skin
diseases,
as
well
as
osteoporosis,
metabolic,
cardiovascular
and
inflammatory
diseases.
The
Company
strives
to
develop
drugs
that
are
more
effective
and/or
safer
than
existing
therapies
and
that
are
more
convenient
(taken
orally
or
topically
administered)
and
cost
effective.
Ligand
markets
four
oncology
products
in
the
United
States,
Panretin
gel,
ONTAK,
Targretin
capsules
and
Targretin
gel.
Ligand
is
developing
additional
products
through
its
internal
development
programs
and
has
various
products
in
clinical
development,
including
products
for
larger
market
indications
such
as
Non-small
cell
lung
cancer,
B-cell
Non-Hodgkin's
lymphoma,
psoriasis
and
rheumatoid
arthritis. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | LGND
discovers,
develops
and
markets
new
drugs
that
address
critical
unmet
medical
needs
of
patients
in
areas
of
cancer,
men's
and
women's
health
and
skin
diseases,
as
well
as
osteoporosis,
cardiovascular
and
inflammatory
diseases.
For
the
six
months
ended
6/30/01,
revenues
rose
67%
to
$34.5
million.
Net
loss
before
acct.
change
fell
33%
to
$22.2
million.
Revenues
reflect
higher
sales
of
ONTAK.
Lower
loss
were
partially
offset
by
higher
selling
and
marketing
exp. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| David Robinson, 52 Chairman,
Pres, CEO | $556K | Paul Maier, 53 CFO,
Sr. VP | 250K | William Pettit, 51 Sr.
VP- HR and Admin. | -- | Andres Negro-Vilar, M.D., Ph.D., 61 Sr.
VP, R&D and CSO | 397K | Steven Reich, Ph.D., 55 Sr.
VP- Clinical Research | 286K | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|